The White House is expected to host Regeneron Pharmaceuticals chief executive Richard Meeker for a state dinner next week as the company wins approval for a new drug that could be used in treatment of macular degeneration and cancer. But the words Mr. Meeker will be using in both remarks and in his photos to prepare for the event could backfire.
According to two people familiar with the matter, Mr. Meeker had not signed a proclamation issued by President Trump in 2017 that called for the reduction of red tape to get regulatory agency approvals for generic drugs and devices “as quickly as possible.” The proclamation also outlined a list of agencies to report to the president, including the Federal Trade Commission, Drug Enforcement Administration and the Food and Drug Administration, on their efforts to reduce the federal regulatory burden.
The red tape reduction order came one month after Mr. Meeker had publicly criticized Mr. Trump, saying the administration was taking a “cavalier approach” to regulating the U.S. pharmaceutical industry. Mr. Meeker has previously visited the White House to advocate for easing regulation.
The Regeneron executive did not respond to a request for comment. The White House declined to comment.
From: Katie Thomas
To: Colleen Wren
Sent: Friday, October 05, 2018 6:22 AM
Subject: REGROUNDS President Trump and First Lady Melania Trump welcome Chief Executive of Regeneron Pharmaceuticals Richard Meeker and his wife Helen Marten Meeker for dinner, October 5, 2018 at 5:30 p.m. at the executive residence. Colleen Wren